Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Country-specific optimization of testing rates and unlock measures can help to contain COVID19 infection

View ORCID ProfileUddipan Sarma, View ORCID ProfileBhaswar Ghosh
doi: https://doi.org/10.1101/2020.05.20.20107169
Uddipan Sarma
1Vantage Research, Sivasamy St, CIT Colony, Mylapore, Chennai, Tamil Nadu 600004. India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Uddipan Sarma
  • For correspondence: uddipans{at}gmail.com bhaswar.ghosh{at}iiit.ac.in
Bhaswar Ghosh
2Center for Computational Natural Sciences, International Institute of Information Technology, Hyderabad 500032, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Bhaswar Ghosh
  • For correspondence: uddipans{at}gmail.com bhaswar.ghosh{at}iiit.ac.in
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

In response to the COVID19 outbreak many countries have implemented lockdown to ensure social distancing. However, long lockdowns globally affected the livelihood of millions of people resulting in subsequent unlocks that started a second wave of infection in multiple countries. Unlocking of the economies critically imposes extra burden on testing and quarantine of the infected people to keep the reproduction number (R0) <1. This, as we demonstrate, requires optimizing a cost-benefit trade-off between testing rate and unlock extent. We delineate a strategy to optimize the trade-off by utilizing a data-trained epidemic model and coupling it with a stochastic agent based model to implement contact tracing. In a country specific manner, we quantitatively demonstrate how combination of unlock and testing can maintain R0 <1.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No funding agencies supported the study.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Not applicable

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Following the COVID19 outbreak lockdowns of different degrees were implemented worldwide and at present multiple countries are already starting the process of unlocking socio-economic activities. As a preventive measure many countries are ramping up the testing rates to ensure detecting new cases owing to such unlocks. However it remains unknown if the testing rate and unlock degree can be coupled in a data-driven manner. In the revised manuscript, we quantitatively demonstrate, the allowed extent of unlock is critically limited by the capacity of testing rates in a country specific manner. Model calibration shows countries like USA or India have very high transmission rates requiring a significant ramping up of the testing rates in order to unlock even by 40%, for instance, whereas countries like Austria, Australia do not have much necessity for augmenting their current testing rates due to their low transmission rates. Such information can also help guide optimal spending on testing, especially in countries where transmission rate is low.

Data Availability

Details of the model simulation and fitting are available upon reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted September 08, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Country-specific optimization of testing rates and unlock measures can help to contain COVID19 infection
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Country-specific optimization of testing rates and unlock measures can help to contain COVID19 infection
Uddipan Sarma, Bhaswar Ghosh
medRxiv 2020.05.20.20107169; doi: https://doi.org/10.1101/2020.05.20.20107169
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Country-specific optimization of testing rates and unlock measures can help to contain COVID19 infection
Uddipan Sarma, Bhaswar Ghosh
medRxiv 2020.05.20.20107169; doi: https://doi.org/10.1101/2020.05.20.20107169

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)